OA12845A - Single dose azithromycin for treating respiratory infections. - Google Patents

Single dose azithromycin for treating respiratory infections. Download PDF

Info

Publication number: OA12845A
Authority: OA; OAPI
Prior art keywords: dose; pharmaceutical composition; azithromycin; single dose; human
Prior art date: 2001-08-21

Application number

OA1200400048A

Other languages

English (en)

Inventor

Michael William Dunne

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-21

Filing date

2002-07-31

Publication date

2006-09-15

2002-07-31 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-09-15 Publication of OA12845A publication Critical patent/OA12845A/en

Links

229960004099 azithromycin Drugs 0.000 title claims abstract description 42
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 41
206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 15
208000022760 infectious otitis media Diseases 0.000 claims description 14
230000037396 body weight Effects 0.000 claims description 12
108090000623 proteins and genes Proteins 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims 12
239000003937 drug carrier Substances 0.000 claims 2
210000002345 respiratory system Anatomy 0.000 claims 1
238000000034 method Methods 0.000 abstract description 11
208000015181 infectious disease Diseases 0.000 description 15
241000606768 Haemophilus influenzae Species 0.000 description 10
244000052769 pathogen Species 0.000 description 9
238000002560 therapeutic procedure Methods 0.000 description 9
206010033078 Otitis media Diseases 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 4
241000588655 Moraxella catarrhalis Species 0.000 description 3
241000193996 Streptococcus pyogenes Species 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
241000197194 Bulla Species 0.000 description 2
241000194032 Enterococcus faecalis Species 0.000 description 2
208000002352 blister Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000037406 food intake Effects 0.000 description 2
238000011556 gerbil model Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
210000003454 tympanic membrane Anatomy 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
208000006374 Uterine Cervicitis Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
SRMPHJKQVUDLQE-KUJJYQHYSA-N azithromycin dihydrate Chemical compound O.O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 SRMPHJKQVUDLQE-KUJJYQHYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
206010008323 cervicitis Diseases 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
210000000959 ear middle Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

OA1200400048A 2001-08-21 2002-07-31 Single dose azithromycin for treating respiratory infections. OA12845A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31386701P	2001-08-21	2001-08-21

Publications (1)

Publication Number	Publication Date
OA12845A true OA12845A (en)	2006-09-15

Family

ID=23217490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400048A OA12845A (en)	2001-08-21	2002-07-31	Single dose azithromycin for treating respiratory infections.

Country Status (25)

Country	Link
US (3)	US20030148964A1 (cs)
EP (1)	EP1418924A2 (cs)
JP (1)	JP2005501862A (cs)
KR (1)	KR20040032942A (cs)
AP (1)	AP1729A (cs)
BG (1)	BG108537A (cs)
BR (1)	BR0211830A (cs)
CA (1)	CA2458135A1 (cs)
CZ (1)	CZ2004232A3 (cs)
EA (1)	EA200400214A1 (cs)
EC (1)	ECSP044985A (cs)
GE (1)	GEP20063812B (cs)
HR (1)	HRP20040163A2 (cs)
HU (1)	HUP0401332A2 (cs)
IL (1)	IL159585A0 (cs)
IS (1)	IS7092A (cs)
MA (1)	MA27059A1 (cs)
MX (1)	MXPA04001605A (cs)
OA (1)	OA12845A (cs)
PL (1)	PL367888A1 (cs)
SK (1)	SK1012004A3 (cs)
TN (1)	TNSN04035A1 (cs)
WO (1)	WO2003018031A2 (cs)
YU (1)	YU8804A (cs)
ZA (1)	ZA200400804B (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1648473B1 (en) *	2003-07-24	2009-01-28	PLIVA HRVATSKA d.o.o.	Single dose fast dissolving azithromycin
WO2005053651A1 (en)	2003-12-04	2005-06-16	Pfizer Products Inc.	Multiparticulate compositions with improved stability
JP2007513147A (ja)	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
RU2331410C2 (ru)	2003-12-04	2008-08-20	Пфайзер Продактс Инк.	Способ получения фармацевтических мультичастиц
US6984403B2 (en)	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
ES2798263T3 (es)	2005-12-08	2020-12-10	Insmed Inc	Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US9119783B2 (en)	2007-05-07	2015-09-01	Insmed Incorporated	Method of treating pulmonary disorders with liposomal amikacin formulations
US20090005326A1 (en) *	2007-06-26	2009-01-01	Idexx Laboratories, Inc.	Single dose roxithromycin
US20090197956A1 (en) *	2008-02-04	2009-08-06	Arbor Pharmaceuticals, Inc.	Treatment of acute otitis media with xylitol and n-acetylcysteine
WO2009114810A2 (en) *	2008-03-14	2009-09-17	The Florida International Uinversity Board Of Trustees	Use of ellagitannins as inhibitors of bacterial quorum sensing
WO2012170356A1 (en)	2011-06-04	2012-12-13	Rochester General Hospital Research Institute	Compositions and methods related to p6 of haemophilus influenzae
CA2891487A1 (en)	2012-11-29	2014-06-05	Insmed Incorporated	Stabilized vancomycin formulations
MX384843B (es)	2014-05-15	2025-03-14	Insmed Inc	Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3773505B1 (en)	2018-03-30	2026-04-29	Insmed Incorporated	Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en)	2018-05-02	2022-03-23	Insmed Incorporated	PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
US20230149428A1 (en) *	2020-02-14	2023-05-18	Asklepios Biopharmaceutical, Inc.	Method of treating gene therapy associated toxicity with antibiotics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US53264A (en) *		1866-03-20		Improved ditching-machine
SI7910768A8 (en) *	1979-04-02	1996-06-30	Pliva Pharm & Chem Works	Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
YU43006B (en) *	1981-03-06	1989-02-28	Pliva Pharm & Chem Works	Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
MX12213A (es) *	1987-07-09	1993-05-01	Pfizer	Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) *	1987-09-10	1989-03-23	Pfizer	Azithromycin and derivatives as antiprotozoal agents
YU45590A (sh) *	1990-03-07	1992-07-20	PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o.	Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
TW271400B (cs) *	1992-07-30	1996-03-01	Pfizer
WO1994026758A1 (en) *	1993-05-19	1994-11-24	Pfizer Inc.	Intermediate for azithromycin
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
DE69524214T3 (de) *	1994-05-06	2008-05-15	Pfizer Inc.	Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
HRP980189B1 (en) *	1998-04-06	2004-04-30	Pliva Pharm & Chem Works	Novel 15-membered lactams ketolides
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US20040053264A1 (en) *	2002-02-01	2004-03-18	Park Sung Sup	Clinical panel assay using DNA chips

2002
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Ceased
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/en not_active Ceased
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-07-31 CA CA002458135A patent/CA2458135A1/en not_active Abandoned
- 2002-07-31 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-07-31 EP EP02753170A patent/EP1418924A2/en not_active Withdrawn
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HRP20040163A2 (en)	2005-02-28
MA27059A1 (fr)	2004-12-20
MXPA04001605A (es)	2004-07-08
IS7092A (is)	2003-12-23
IL159585A0 (en)	2004-06-01
YU8804A (sh)	2006-08-17
AP1729A (en)	2007-03-26
US20040023898A1 (en)	2004-02-05
US7067493B2 (en)	2006-06-27
JP2005501862A (ja)	2005-01-20
ECSP044985A (es)	2004-04-28
KR20040032942A (ko)	2004-04-17
AP2004002968A0 (en)	2004-03-31
TNSN04035A1 (fr)	2006-06-01
BG108537A (bg)	2005-02-28
GEP20063812B (en)	2006-05-10
SK1012004A3 (sk)	2005-04-01
HUP0401332A2 (hu)	2004-11-29
US20050250712A1 (en)	2005-11-10
EP1418924A2 (en)	2004-05-19
US20030148964A1 (en)	2003-08-07
EA200400214A1 (ru)	2004-06-24
CZ2004232A3 (cs)	2005-10-12
WO2003018031A2 (en)	2003-03-06
PL367888A1 (en)	2005-03-07
ZA200400804B (en)	2005-05-03
CA2458135A1 (en)	2003-03-06
US6987093B2 (en)	2006-01-17
BR0211830A (pt)	2004-09-08
WO2003018031A3 (en)	2003-10-02

Publication	Publication Date	Title
Barry et al.	1992	Intravenous immunoglobulin therapy for toxic shock syndrome
ZA200400804B (en)	2005-05-03	Single dose azithromycin for treating respirator infections.
UA41995C2 (uk)	2001-10-15	Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
Dunne et al.	2017	A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270)
JP2002523437A5 (cs)	2006-10-19
US5550153A (en)	1996-08-27	Method for treating heartworm-infected canines
HUP0002125A2 (hu)	2000-12-28	Tökéletesített retard hatású mikróbaellenes szerek
Kavi et al.	1988	A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin
AU2002313574A1 (en)	2003-03-10	Single dose azithromycin for treating respiratory infections
Kafetzis et al.	1987	Efficacy and safety of roxithromycin in treating paediatric patients. A European multicentre study
CN102327599A (zh)	2012-01-25	用于治疗骨髓增生异常综合征的组合物和方法
US20060210483A1 (en)	2006-09-21	Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060142254A1 (en)	2006-06-29	Antipyretic preparation containing xylitol
CN114375200A (zh)	2022-04-19	治疗传染病的药物和方法
JP2023533472A5 (cs)	2024-07-09
AkŞÍT et al.	1998	Seasonal benzathine penicillin G prophylaxis for recurrent streptococcal pharyngitis in children
RU2498803C1 (ru)	2013-11-20	Противотуберкулезное лекарственное средство
US20060057133A1 (en)	2006-03-16	Topical pathogenic-tissue-destroying liquid
EP0664130A1 (en)	1995-07-26	External preparation for treating hemorrhoidal diseases
Fiese	1957	Therapy of coccidioidomycosis
CA2199255A1 (en)	1996-03-14	Enteral vaccine for vaginal infections
RU2189811C2 (ru)	2002-09-27	Способ профилактики и лечения респираторных болезней телят
RU2333766C2 (ru)	2008-09-20	Способы введения далбаванцина для лечения бактериальных инфекций
DuPont	1996	Overview of clinical experience of pefloxacin in gastrointestinal infections
CA2407724A1 (en)	2001-11-08	Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal